je.st
news
Tag: merck
Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps
2014-11-04 06:00:00| Beef
Merck Animal Health is announcing significant progress in the implementation of its Zilmax Five-Step Plan. With insights from the company’s advisory board, an extensive assessment and analysis of existing, as well as new product data, was conducted. Additionally, Merck Animal Health obtained the input of industry experts, business partners and customers about the product and its use. In a release, Merck Animal Health provided an update on the Zilmax Five-Step Plan, and announced the following steps: read more
Tags: health
plan
update
steps
Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients
2014-11-03 11:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection. Results were presented as a poster (#0434) and oral presentation by Dr. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCarmen de Gourville, 267-664-0146orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
study
phase
patients
Twitter, DuPont, Bank of Americaand Merck are part of Zacks Earnings Preview:
2014-10-28 09:55:32| Paper - Topix.net
Every day, Zacks.com makes their Bull Stock of the Day available, free of charge. To see it, click here .
Tags: part
bank
preview
earnings
Merck Announces Third-Quarter 2014 Financial Results
2014-10-27 12:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Third-Quarter 2014 Non-GAAP EPS of $0.90, Excluding Certain Items, and GAAP EPS of $0.31 Narrows 2014 Full-Year Non-GAAP EPS Target to $3.46 to $3.50, Excluding Certain Items; Updates 2014 Full-Year GAAP EPS Target to $4.06 to $4.29; Now Expects 2014 Full-Year Revenues to be Between $42.4 Billion and $42.8 Billion Generated Worldwide Sales of $10.6 Billion, a Decrease of 4 Percent, Reflecting Unfavorable Impact of Divested Products, Patent Expiries and Decline in Sales of Hepatitis C Products Increased Sales of Acute Care, Immunology, Diabetes and Animal Health Products FDA Approved KEYTRUDA for the Treatment of Advanced Melanoma in Patients Who Have Progressed after Other Therapies and BELSOMRA for the Treatment of Insomnia KEYTRUDA Received Breakthrough Therapy Designation from the FDA for Patients with Advanced Non-Small Cell Lung Cancer Who Have Progressed Following Platinum-Containing Chemotherapy WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2014. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Lainie Keller, 908-236-5036orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
2014-10-27 11:45:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma Kinase (ALK) rearrangement-negative non-small cell lung cancer (NSCLC) whose disease has progressed on or following platinum-based chemotherapy. Language: English Contact: Media Contacts:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor Contacts:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
cell
cancer
therapy
Sites : [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] next »